RU2007146769A - Бициклические производные и их применение в качестве модуляторов ионых каналов - Google Patents
Бициклические производные и их применение в качестве модуляторов ионых каналов Download PDFInfo
- Publication number
- RU2007146769A RU2007146769A RU2007146769/04A RU2007146769A RU2007146769A RU 2007146769 A RU2007146769 A RU 2007146769A RU 2007146769/04 A RU2007146769/04 A RU 2007146769/04A RU 2007146769 A RU2007146769 A RU 2007146769A RU 2007146769 A RU2007146769 A RU 2007146769A
- Authority
- RU
- Russia
- Prior art keywords
- ring
- aliphatic group
- independently selected
- halogen
- pain
- Prior art date
Links
- 102000004310 Ion Channels Human genes 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract 34
- 239000000203 mixture Substances 0.000 claims abstract 3
- 125000002619 bicyclic group Chemical group 0.000 claims abstract 2
- -1 1,2-methylenedioxy Chemical group 0.000 claims 22
- 229910052736 halogen Inorganic materials 0.000 claims 19
- 150000002367 halogens Chemical group 0.000 claims 19
- 125000001931 aliphatic group Chemical group 0.000 claims 18
- 125000001424 substituent group Chemical group 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 13
- 208000002193 Pain Diseases 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 7
- 125000005842 heteroatom Chemical group 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000001118 alkylidene group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 208000008035 Back Pain Diseases 0.000 claims 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 206010028836 Neck pain Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- 206010037779 Radiculopathy Diseases 0.000 claims 2
- 208000008765 Sciatica Diseases 0.000 claims 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 230000001272 neurogenic effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 206010061928 radiculitis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 206010061533 Myotonia Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 108010052164 Sodium Channels Proteins 0.000 claims 1
- 102000018674 Sodium Channels Human genes 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000001037 epileptic effect Effects 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 125000000593 indol-1-yl group Chemical group [H]C1=C([H])C([H])=C2N([*])C([H])=C([H])C2=C1[H] 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- MCRAICCHFJHVDC-UHFFFAOYSA-N n-(4-cyano-3-methylsulfanyl-1h-pyrazol-5-yl)-1-methyl-2-oxo-4-(trifluoromethyl)quinoline-6-sulfonamide Chemical compound CSC1=NNC(NS(=O)(=O)C=2C=C3C(=CC(=O)N(C)C3=CC=2)C(F)(F)F)=C1C#N MCRAICCHFJHVDC-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000015706 neuroendocrine disease Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 230000001148 spastic effect Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 claims 1
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 0 C*CCC1=CCN(C)C1 Chemical compound C*CCC1=CCN(C)C1 0.000 description 4
- LBUJPTNKIBCYBY-UHFFFAOYSA-N C1CNc2ccccc2C1 Chemical compound C1CNc2ccccc2C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 1
- LRQUEWJWKNRZOH-UHFFFAOYSA-N CCN(C)[n]1cnnc1 Chemical compound CCN(C)[n]1cnnc1 LRQUEWJWKNRZOH-UHFFFAOYSA-N 0.000 description 1
- QSDIXCHNEBIQHJ-UHFFFAOYSA-N CN1C=CNC1 Chemical compound CN1C=CNC1 QSDIXCHNEBIQHJ-UHFFFAOYSA-N 0.000 description 1
- ANFXTILBDGTSEG-UHFFFAOYSA-N CN1C=NCC1 Chemical compound CN1C=NCC1 ANFXTILBDGTSEG-UHFFFAOYSA-N 0.000 description 1
- FNOKJRGVMILSFT-UHFFFAOYSA-N CN1N=CCC1 Chemical compound CN1N=CCC1 FNOKJRGVMILSFT-UHFFFAOYSA-N 0.000 description 1
- NFHQYWPOTLXIQP-UHFFFAOYSA-N CN1NCCC1 Chemical compound CN1NCCC1 NFHQYWPOTLXIQP-UHFFFAOYSA-N 0.000 description 1
- UQFQONCQIQEYPJ-UHFFFAOYSA-N C[n]1nccc1 Chemical compound C[n]1nccc1 UQFQONCQIQEYPJ-UHFFFAOYSA-N 0.000 description 1
- MXZANEWAFZMPKW-UHFFFAOYSA-N N[n]1cncc1 Chemical compound N[n]1cncc1 MXZANEWAFZMPKW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68151905P | 2005-05-16 | 2005-05-16 | |
| US60/681,519 | 2005-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007146769A true RU2007146769A (ru) | 2009-06-27 |
Family
ID=36915025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007146769/04A RU2007146769A (ru) | 2005-05-16 | 2006-05-12 | Бициклические производные и их применение в качестве модуляторов ионых каналов |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US7745629B2 (enExample) |
| EP (1) | EP1888558B1 (enExample) |
| JP (2) | JP2008540661A (enExample) |
| KR (1) | KR20080021030A (enExample) |
| CN (1) | CN101218226A (enExample) |
| AT (1) | ATE527251T1 (enExample) |
| AU (1) | AU2006247478A1 (enExample) |
| CA (1) | CA2608599A1 (enExample) |
| IL (1) | IL187382A0 (enExample) |
| MX (1) | MX2007014486A (enExample) |
| NO (1) | NO20076447L (enExample) |
| RU (1) | RU2007146769A (enExample) |
| WO (1) | WO2006124744A1 (enExample) |
| ZA (1) | ZA200710332B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| JP2008540539A (ja) | 2005-05-10 | 2008-11-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャンネルの調節因子としての二環系誘導体 |
| RU2008113836A (ru) * | 2005-09-09 | 2009-10-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Бициклические производные в качестве модуляторов потенциалозависимых ионных каналов |
| WO2007050522A1 (en) * | 2005-10-21 | 2007-05-03 | Vertex Pharmaceuticals Incorporated | Derivatives for modulation of ion channels |
| CA2633653A1 (en) * | 2005-12-21 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| WO2008101029A2 (en) * | 2007-02-13 | 2008-08-21 | Xenon Pharmaceuticals Inc. | Use of thiazole, oxazole and imidazole compounds for the treatment of sodium channel-mediated diseases or conditions |
| US8193194B2 (en) | 2007-05-25 | 2012-06-05 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| US7994174B2 (en) * | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
| WO2009045381A1 (en) * | 2007-10-04 | 2009-04-09 | Merck & Co., Inc. | N-substituted oxindoline derivatives as calcium channel blockers |
| ES2377172T3 (es) * | 2007-11-13 | 2012-03-23 | Vertex Pharmaceuticals Incorporated | Derivados heterocíclicos como moduladores de canales iónicos |
| RU2010123781A (ru) | 2007-11-13 | 2011-12-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Производные 4-(2-фенил)-морфолино)-2-оксопирролидин-1-ил)-n-(тиазол-2-ил)бензолсульфонамида и родственные соединения в качестве модуляторов ионных каналов для лечения боли |
| CN101978787A (zh) * | 2008-04-30 | 2011-02-16 | 夏普株式会社 | 照明装置和显示装置 |
| KR20110025855A (ko) * | 2008-07-01 | 2011-03-11 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널의 조절제로서의 헤테로사이클릭 유도체 |
| US20130109672A1 (en) | 2010-04-29 | 2013-05-02 | The United States Of America,As Represented By The Secretary, Department Of Health And Human Service | Activators of human pyruvate kinase |
| EP2788332A1 (en) | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| US8889741B2 (en) * | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| US9776995B2 (en) | 2013-06-12 | 2017-10-03 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| MX2016010056A (es) | 2014-02-06 | 2016-11-15 | Abbvie Inc | 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. |
| GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
| GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
| US11993581B2 (en) | 2018-07-09 | 2024-05-28 | Lieber Institue, Inc | Pyridazine compounds for inhibiting Nav1.8 |
| JP2021530478A (ja) | 2018-07-09 | 2021-11-11 | リーバー インスティチュート インコーポレイテッドLieber Institute, Inc. | ＮａＶ１．８を阻害するためのピリジンカルボキシアミド化合物 |
| PL4299135T3 (pl) | 2019-06-18 | 2025-11-12 | Pfizer Inc. | Pochodne benzizoksazolosulfonamidu |
| JP7739051B2 (ja) | 2020-06-10 | 2025-09-16 | アムジエン・インコーポレーテツド | シクロブチルジヒドロキノリンスルホンアミド化合物 |
| CN115073370B (zh) * | 2021-03-10 | 2024-12-17 | 成都硕德药业有限公司 | 新型烷基氨类化合物或盐、异构体、其制备方法及用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US5869478A (en) | 1995-06-07 | 1999-02-09 | Bristol-Myers Squibb Company | Sulfonamido substituted benzopyran derivatives |
| EP1011677A4 (en) * | 1997-08-28 | 2002-03-20 | Bristol Myers Squibb Co | 4-ARYL-3-AMINOQUINOLEIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS |
| GB0217431D0 (en) * | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
| US7157577B2 (en) * | 2003-03-07 | 2007-01-02 | Sugen Inc. | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors |
| US7009052B2 (en) * | 2003-03-20 | 2006-03-07 | Warner Lambert Company Llc | Sulfonamide derivatives |
| KR20060073930A (ko) | 2003-08-08 | 2006-06-29 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체 |
| US7615563B2 (en) | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| JP2008540539A (ja) | 2005-05-10 | 2008-11-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャンネルの調節因子としての二環系誘導体 |
| KR20080019693A (ko) | 2005-06-09 | 2008-03-04 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널 조절인자로서의 인단 유도체 |
| RU2008113836A (ru) | 2005-09-09 | 2009-10-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Бициклические производные в качестве модуляторов потенциалозависимых ионных каналов |
| CA2624831A1 (en) | 2005-10-12 | 2007-04-26 | Vertex Pharmaceuticals Incorporated | Biphenyl derivatives as modulators of voltage gated ion channels |
| WO2007050522A1 (en) | 2005-10-21 | 2007-05-03 | Vertex Pharmaceuticals Incorporated | Derivatives for modulation of ion channels |
| CA2633653A1 (en) | 2005-12-21 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| US7994174B2 (en) | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
| ES2377172T3 (es) | 2007-11-13 | 2012-03-23 | Vertex Pharmaceuticals Incorporated | Derivados heterocíclicos como moduladores de canales iónicos |
| RU2010123781A (ru) | 2007-11-13 | 2011-12-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Производные 4-(2-фенил)-морфолино)-2-оксопирролидин-1-ил)-n-(тиазол-2-ил)бензолсульфонамида и родственные соединения в качестве модуляторов ионных каналов для лечения боли |
| US8697739B2 (en) * | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
-
2006
- 2006-05-12 CN CNA2006800252561A patent/CN101218226A/zh active Pending
- 2006-05-12 AU AU2006247478A patent/AU2006247478A1/en not_active Abandoned
- 2006-05-12 WO PCT/US2006/018669 patent/WO2006124744A1/en not_active Ceased
- 2006-05-12 US US11/432,997 patent/US7745629B2/en active Active
- 2006-05-12 CA CA002608599A patent/CA2608599A1/en not_active Abandoned
- 2006-05-12 JP JP2008512394A patent/JP2008540661A/ja not_active Ceased
- 2006-05-12 KR KR1020077029355A patent/KR20080021030A/ko not_active Withdrawn
- 2006-05-12 RU RU2007146769/04A patent/RU2007146769A/ru not_active Application Discontinuation
- 2006-05-12 AT AT06770340T patent/ATE527251T1/de not_active IP Right Cessation
- 2006-05-12 MX MX2007014486A patent/MX2007014486A/es not_active Application Discontinuation
- 2006-05-12 EP EP06770340A patent/EP1888558B1/en not_active Not-in-force
- 2006-05-12 ZA ZA200710332A patent/ZA200710332B/xx unknown
-
2007
- 2007-11-15 IL IL187382A patent/IL187382A0/en unknown
- 2007-12-14 NO NO20076447A patent/NO20076447L/no not_active Application Discontinuation
-
2010
- 2010-04-16 US US12/761,502 patent/US8314125B2/en active Active
-
2012
- 2012-03-28 JP JP2012074138A patent/JP2012126744A/ja not_active Withdrawn
- 2012-11-16 US US13/679,028 patent/US8536195B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20100204255A1 (en) | 2010-08-12 |
| ZA200710332B (en) | 2009-03-25 |
| US20130084639A1 (en) | 2013-04-04 |
| US8314125B2 (en) | 2012-11-20 |
| EP1888558B1 (en) | 2011-10-05 |
| AU2006247478A1 (en) | 2006-11-23 |
| CN101218226A (zh) | 2008-07-09 |
| US8536195B2 (en) | 2013-09-17 |
| JP2012126744A (ja) | 2012-07-05 |
| EP1888558A1 (en) | 2008-02-20 |
| CA2608599A1 (en) | 2006-11-23 |
| JP2008540661A (ja) | 2008-11-20 |
| US20080119453A1 (en) | 2008-05-22 |
| NO20076447L (no) | 2008-02-08 |
| MX2007014486A (es) | 2008-02-12 |
| WO2006124744A1 (en) | 2006-11-23 |
| ATE527251T1 (de) | 2011-10-15 |
| US7745629B2 (en) | 2010-06-29 |
| KR20080021030A (ko) | 2008-03-06 |
| IL187382A0 (en) | 2008-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007146769A (ru) | Бициклические производные и их применение в качестве модуляторов ионых каналов | |
| RU2007145434A (ru) | Бициклические производные в качестве модуляторов ионных каналов | |
| CA3122317C (en) | Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound | |
| AU2019414550B2 (en) | FAK inhibitor and drug combination thereof | |
| JP7295169B2 (ja) | Ｂｔｋ阻害活性を有するピリミジン及びピリジン化合物を用いた癌の治療方法 | |
| CA2828478C (en) | Serine/threonine kinase inhibitors | |
| JP6782255B2 (ja) | ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法 | |
| WO2013001310A1 (en) | Macrocyclic compounds and their use as cdk8 inhibitors | |
| JP2022506887A (ja) | 窒素含有縮合複素環系ｓｈｐ２阻害剤化合物、製造方法及び使用 | |
| JP2008540661A5 (enExample) | ||
| CN104080773B (zh) | 氮杂环化合物 | |
| RU2007148504A (ru) | Индановые производные в качестве модуляторов ионных каналов | |
| JP2023527242A (ja) | Ａｘｌ阻害剤であるピリミジン系化合物 | |
| BR112020000122A2 (pt) | derivados da n-(3-(2-(4-clorofenóxi)acetamido)biciclo[1.1.1] pentan-1-il)-2-ciclobutano-1-carboxamida e compostos relacionados como inibidores do atf4 para tratamento contra o câncer e outras doenças | |
| JP2021527098A (ja) | 縮合チオフェン化合物 | |
| WO2018225093A1 (en) | Chemical compounds as atf4 pathway inhibitors | |
| EA024109B1 (ru) | Ингибиторы протеинкиназ | |
| BR112012004453A2 (pt) | Composto inibidor de proteína quinase, sua composição farmacêutica e seu uso | |
| ES2617878T3 (es) | Inhibidores de tubulina basados en la pirazina | |
| BR112020000086A2 (pt) | derivados de 2-(4-clorofenóxi)-n-((1-(2-(4-clorofenóxi) etinazetidin-3-il) metil) acetamida e compostos relacionados como inibidores de atf4 para tratamento de câncer e outras doenças | |
| CN105793261A (zh) | 吡唑并嘧啶化合物 | |
| WO2018008711A1 (ja) | Ｅｐ４拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ | |
| JP2022542669A (ja) | Ｉｒａｋ４キナーゼ阻害剤及びその調製方法 | |
| RU2008113836A (ru) | Бициклические производные в качестве модуляторов потенциалозависимых ионных каналов | |
| JP6615207B2 (ja) | 複素環式化合物及びその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100504 |